Coronary microvascular dysfunction was found to be associated with an increased risk for cardiovascular events and cardiac dysfunction in patients with chronic kidney disease, according to a study published in Circulation. In this longitudinal study, 352 patients without overt coronary, valvular, or end-organ disease, who underwent cardiac stress positron emission tomography (PET), echocardiogram, and renal function assessment at Brigham and Womens Hospital in Boston, Massachusetts, between 2006 and 2016 were enrolled Continue reading →

INTRODUCTION Anthracycline is a group of chemotherapeutic drugs that are being actively used to treat broad types of cancer (1, 2), but the major clinical complication for these antibiotics is their dose-dependent cardiotoxicity (1). Several mechanisms have been proposed for anthracycline-induced cardiotoxicity (AIC), including topoisomerase II (coded by TOP2B) as a primary mediator (3). On the basis of these mechanisms, dexrazoxane, an iron chelator, has been successfully developed as the only U.S Continue reading →